No Data
Trending Stocks as U.S.market Posts Another Week of Rebound
Hims & Hers Short Interest at Critical Levels After Best Weekly Gain: Report
Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why.
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Novo Nordisk Says Oral Version of Wegovy Accepted for FDA Review
The FDA Action Date To Decide On The Wegovy Oral Formulation NDA Will Be In Q4 2025